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 Intramuscular adipose tissue (IMAT) is an important negative predictor of muscle 
and mobility function in older adults. While IMAT has been theorized to increase with 
aging, more recent evidence suggests that IMAT may be a byproduct of inactivity rather 
than aging per se. The mechanism of IMAT’s influence on muscle and mobility function 
is unknown but similar to the negative consequences attributed to other ectopic fat 
depots, may involve an inflammatory pathway. In order to clarify if IMAT is an 
obligatory consequence of age or if it is related to inactivity, the primary aim of this study 
was to compare IMAT, muscle and mobility function, and muscular inflammation in age 
and BMI matched older frail and nonfrail adults.  A secondary aim was to examine the 
relationship of IMAT and visceral adipose tissue (VAT), muscular inflammation, muscle 
function and mobility function in a subgroup of older adults. Two groups of older 
nonobese adults were recruited. A sedentary frail group was classified as at least 
moderately frail with modified physical performance test scores of < 25 and an active 
nonfrail group had modified physical performance test scores of > 32. Magnetic 
resonance imaging (MRI) was used to determine mean cross sectional area of thigh 
IMAT and VAT. Maximal voluntary isometric contractions were used to determine 
muscle function, and 6 minute walk and stair ascent time were used to determine mobility 
function.  A sub group of participants from both groups who were free from disease and 
medications known to influence inflammation underwent percutaneous muscle biopsies 
 iv  
of the vastus lateralis.  Western blot and real time polymerase chain reaction were used to 
determined local muscular expression of mRNA and protein for the proinflammatory 
cytokines interleukin 6 (IL-6) and tumor necrosis alpha (TNF-a). We found significant 
differences in IMAT, and IL-6 mRNA and protein expression between frail and nonfrail 
adults.  We also found significant correlations between IMAT, VAT, IL-6, and muscle 
and mobility function. These findings suggest that IMAT is a product of inactivity and 
disease rather then aging alone and provide a potential mechanistic link between 
increased IMAT and decreased muscle and mobility function in older adults. 
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Muscle’s structural composition is an important factor underlying muscle strength 
and physical function in older adults. There is an increasing amount of research to 
support the clear disassociation between the loss of muscle lean tissue mass and strength 
with aging.1-3 This disassociation between lean tissue and strength implies factors other 
than lean muscle mass alone are responsible for the decreases in strength and function 
seen with aging.  Intramuscular adipose tissue (IMAT), or the fat found beneath the fascia 
of a muscle, is a significant predictor of both muscle function and mobility function in 
older adults.4-7  
The majority of the work concerning the relationship of IMAT with muscle and 
physical function has to date been reported from the Health ABC study.4, 8-10 In this large 
study of over 2,500 healthy nonmobility limited individuals age 70-79 Goodpaster et al. 
first reported that increased levels of IMAT were associated with both decreased muscle 
strength and muscle quality, or the force produced per unit of muscle area.4 In this same 
study population of older adults Visser et al. found that individuals with the highest levels 
of IMAT also had the lowest mobility scores,7 and in a follow up study 2.5 years later 
that those with the highest amounts of IMAT and the lowest quartile of strength were 
most at risk for developing self reported mobility limitations in the future.9  
 In addition to the Health ABC studies, smaller clinical studies have also 
demonstrated similar relationships between IMAT and mobility function in older adults. 
Hilton et al. showed that in 9 obese individuals with diabetes IMAT levels are highly 
correlated (r=-0.92) with mobility function as measured by the physical performance 
test.5 More recently, in the only study to date to look at mobility limited individuals, 
Marcus et al. examined the relationship of IMAT with mobility and strength in older 
mobility limited adults.6 In this study of over 100 mobility limited individuals, multiple 
regression analysis was used to examine the relationships between IMAT, lean muscle 
tissue, strength, BMI and mobility function (as measured by six minute walk, timed up 
and go, stair ascent and stair descent).  In every analysis IMAT was one of, if not the 
most, robust predictors of mobility function.6 Taken together, these studies have 
demonstrated a clear relationship between IMAT and muscle and mobility function in 
older adults and IMAT is now recognized as a significant structural component 
associated with muscle related dysfunctions in this vulnerable population. 
  The reason for increased IMAT levels in older adults however, is unknown.  There 
is ongoing debate about if IMAT is an inevitable consequence of aging or alternatively a 
consequence of inactivity that often accompanies aging. Numerous studies theorize that 
an increase in IMAT is an associated consequence of aging.1, 11-13  Marcus et al. found a 
moderate correlation (r=0.47) between aging and IMAT12 and Gallagher et al. 
demonstrated an average increase of 9g/year in IMAT in sedentary adults spanning from 
20 to 80 years old.11 In perhaps the most compelling study to date examining aging and 
IMAT, Delmonico et al. reported, a consistent increase of 16-75% in IMAT over 5 years 
in healthy adults between the ages of 70 and 79 (n>1500).1 This increase in IMAT was 
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consistently found in those who were weight stable, those who gained weight (a 75% 
increase in IMAT) and surprisingly even in those who lost weight (a 16% increase in 
IMAT). However this study did not fully account for disease state or activity levels and 
more recent studies14-16 have suggested that increased levels of IMAT may be instigated 
by either or both of these variables. 
Increased IMAT is found in individuals with a higher body mass index4 and in 
those with numerous chronic disease conditions that are often associated with decreased 
activity levels such as chronic kidney disease17 and diabetes.18-20 Higher levels of IMAT 
are also noted postspinal cord injury21 and postcerebrovascular accident22 and it has been 
speculated that increased levels of IMAT postinjury are related to decreased muscle 
activity, as spasticity can blunt the increase in IMAT.23 Manini et al. also found increased 
IMAT levels in the thigh and calf muscles of young (19-28 years old) individuals after 30 
days of single limb suspension.  While muscle volume decreased 7.4% and 7.7% in the 
thigh and calf respectively, IMAT volume increased 15% in the thigh and 20% in the calf 
suggesting that even in young healthy individuals increased IMAT is a consequence of 
decreased activity levels. Additionally, the relative accumulation of IMAT, in this study, 
exceeded the loss of muscle volume in both the thigh and calf. A regression analysis 
demonstrated that the loss of muscle mass was only able to explain 26% of the variance 
in IMAT accumulation suggesting that the accumulation of IMAT is more than just a 
replacement of lost muscle mass. Further evidence to support the notion that increased 
IMAT is a consequence of inactivity rather then aging per se can be found in cross 
sectional studies of older adults examining activity levels and IMAT. Tuttle et al. found a 
moderate relationship in older obese adults with diabetes between the volume of IMAT in 
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the calf and the number of steps taken per day (r=-0.44, p<0.05).15 Wroblewski et al. 
conducted a cross sectional study that examined the relationship of IMAT and age in 
master athletes. This cross sectional study examined 40 master athletes age 40-81 
categorized into 10 year age groups 40-49,50-59, 60-69 and 70 plus.  They reported no 
significant differences in the amount of IMAT between the age groups and concluded 
that increases in IMAT are not inevitable with aging but are likely related to factors such 
as muscle disuse and disease.  
The finding that physical activity can mitigate increased IMAT provides 
additional evidence linking inactivity and IMAT accumulation.  Goodpaster et al. 
identified that walking two times per week for 12 months resulted in a blunting of 
increases in IMAT in the midthigh of healthy mobile older adults age 70-89. The control 
group in this study, who did not participate in any physical activity intervention, had an 
average increase of 18% in IMAT over 12 months.  However, the active intervention 
group that walked an average of just two times per week for the 12 months had only a 2% 
increase in IMAT.  Furthermore multiple studies have demonstrated that aerobic, 
resistive, or the combination of the two results in decreases in IMAT levels post 
training.12, 24-27 Marcus et al. reported an 11% decrease in IMAT with 12 weeks of 
resistance training in older individuals with multiple comorbidities12 and Durheim et al. 
found that 8-9 months of aerobic training resulted in decreases in IMAT in older men.24 
IMAT is consistently negatively associated with muscle and mobility function.4, 5, 
7, 9, 14 While it is becoming increasingly clear that IMAT may be more a product of the 
inactivity that often accompanies aging rather than simply age itself, whether IMAT is 
merely a marker of muscle dysfunction or if it plays a more active role in muscle and 
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mobility dysfunction remains unknown.  The potential role of IMAT, and adipose tissue 
in general is evolving. 
Adipose tissue is no longer considered to be an inert storage depot for extra 
calories but is now known to be an active endocrine organ that, among other things plays 
an important role as the initiator of the chronic inflammatory response.28, 29 Chronic 
inflammation, a long term elevation of proinflammatory cytokines, is one of the most 
important physiological correlates of the frailty syndrome.30, 31 High levels of 
proinflammatory cytokines in older individuals are related to an increased risk of 
mortality,32 sarcopenia,33, 34 reduced muscle strength,10 and decreased mobility.35, 36  
Visceral adipose tissue (VAT) is an active endocrine tissue that secretes inflammatory 
cytokines and the amount of VAT is strongly related to systemic chronic inflammatory 
levels.37 Like VAT, IMAT may also be a metabolically active component of muscle and a 
potential source of inflammatory regulation in older individuals.1, 8, 14, 38, 39  While IMAT 
is a much smaller fat depot then subcutaneous or visceral adipose tissue, it has been 
associated with systemic levels of the proinflammatory cytokines tumor necrosis alpha 
(TNF-a), Interleukin-6 (IL-6), and c-reactive protein (CRP).38  TNF-a, IL-6, and CRP are 
proinflammatory cytokines released from adipose tissue whose basal levels have been 
closely associated with muscle and mobility function.  While it has been theorized by 
multiple authors1, 8, 14, 38, 39 that IMAT’s negative relationship with muscle and mobility 
function may be attributed to IMAT’s release of proinflammatory cytokines within the 
muscle, to date this relationship has not been clarified.  Increased levels of inflammation 
in the subcutaneous fat as well as in the serum have been associated with increased levels 
of IMAT.38, 39 The independent parallels between inflammation and IMAT, with strength 
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and mobility loss in older individuals, may in fact be linked by the release of 
inflammatory cytokines from IMAT.   
In this dissertation I will examine the relationship of IMAT with local (as 
measured in the muscle) levels of inflammatory cytokines.  I will also examine the 
relationship of IMAT, inflammation, muscle and mobility function in older frail and 
nonfrail individuals. The first chapter of this dissertation will be focused on a review of 
the relationships between inflammation, aging, adiposity, and muscle and mobility 
function in older adults. The second chapter will examine the relationships of IMAT and 
gene expression of IL-6 and TNF-a (both proinflammatory cytokines) with muscle and 
mobility function in both frail and nonfrail older individuals. My third chapter will 
examine location specific fat depots and their relationship with local (as measured in the 
muscle) proinflammatory mRNA and protein expression in older frail and nonfrail adults. 
A discussion of each of these studies as well as their implications and future 
recommendations will be provided within each section.  
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ABSTRACT
Background: Physical therapists treat older individuals, charac-
terized as both a needy and expanding population. Frailty, a pre-
disability condition with links to chronic inflammatory conditions,
is estimated to affect 7% of individuals older than 60 years and
40% of people older than 80 years. Chronic inflammation is one
of the most important physiologic correlates of the frailty syn-
drome and high levels of proinflammatory cytokines, related to
both aging and increasing adiposity in older individuals are relat-
ed to an increased risk of mortality, sarcopenia, reduced muscle
strength and decreased mobility.
Purpose: The purpose of this narrative review is to inform the
physical therapist of the effects of aging and increasing adiposi-
ty on chronic inflammation and the association of inflammation
with muscle loss, strength, and mobility impairments in older
adults; and to review the current evidence to provide clinical rec-
ommendations on physical activity and exercise regimes that
may mitigate chronic inflammation in older adults.
Discussion: As physical therapists help manage and treat an
increasingly older population, understanding how the inflamma-
tory milieu changes with aging and increasing adiposity and how
these changes can be impacted by physical therapists via exer-
cise and physical activity is critical.
Conclusion: Exercise is a potent preventive intervention strate-
gy and countermeasure for chronic inflammation and adiposity.
Exercise can also benefit the frail older individual by combating
the negative effects of chronic inflammation and optimally
balancing the production of pro and anti-inflammatory cytokines.
In addition to providing an anti-inflammatory environment
within muscle to mitigate the effects of chronic inflammation,
exercise has the added benefit of improving muscle mass and
function and decreasing adiposity in older adults.
Key Words: chronic inflammation, frailty, exercise, muscle
(J Geriatr Phys Ther 2011;00:1-9.) 
INTRODUCTION
Physical therapists are increasingly treating an older popu-
lation. By the year 2030 it is expected that 1 in 5 Americans
will be older than 65 years and over the next decade there
will be a 15% increase in the number of Americans older
than 85 years.1 Frailty, a predisability condition with links
to chronic inflammatory conditions, is estimated to affect
7% of individuals older than 60 years and 40% of people
older than 80 years.2 Frailty is marked by dysfunction and
decline across multiple physiologic systems including the
neuromuscular, neuroendocrine, and immune system,3 and
can result in significant health consequences such as
 frequent falls,4,5 fractures,4,5 and an increased risk of
 mortality.6,7 Chronic inflammation is one of the most
important physiologic correlates of the frailty syndrome8,9
and high levels of proinflammatory cytokines in older indi-
viduals are related to an increased risk of mortality,10 sar-
copenia,11,12 reduced muscle strength,13 and decreased
mobility.14,15 Physical therapists help manage and treat an
increasingly older population; therefore, understanding
how the inflammatory milieu changes with aging and how
it can be impacted by physical therapists via exercise and
physical activity is important.
Chronically elevated systemic levels of proinflammatory
cytokines such as tumor necrosis factor-alpha (TNF-!),
interleukin-6 (IL-6), and c-reactive protein (CRP) play a
central role in the etiology of numerous chronic diseases
commonly seen in rehabilitation settings including type 
2 diabetes,16 cardiovascular17-19 and cerebrovascular dis-
ease,20 dementia,21 and sarcopenia.22-24 Cytokines are hor-
mone like proteins that are involved in cell-to-cell commu-
nication that regulate the intensity and duration of the
immune response. Transient increases in the proinflamma-
tory cytokine cascade associated with injury and illness are
part of the normal healing process and assist the immune
system in promoting tissue repair and regeneration by acti-
vation of the complement system and increased phagocyto-
sis. Long-term elevation of proinflammatory cytokines,
however, are detrimental leading ultimately to tissue dam-
age,23,24 muscle loss,13 and even death.10
When tissue is injured due to trauma or illness
macrophages are activated to assist in tissue repair and
regeneration (Figure 1). Activated macrophages secrete
 various cytokines that have autocrine, paracrine, and
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endocrine function. The first actions of these cytokines are
to influence the cells that produced them and then go on to
affect surrounding cells as well. Eventually the production
of these cytokines results in a spill over from the tissue in
which they are produced to increases in circulating levels in
serum which allow these cytokines to act in an endocrine
function. Among the first cytokines released by macrophages
are TNF-! and interluekin-1 (IL-1). Both are powerful
proinflammatory cytokines that result in production of fur-
ther cytokines such as IL-6 as well as the recruitment of
additional macrophages and an induction of acute phase
protein synthesis.
Interleukin-6 has been classified as both a “pro” and an
“anti” inflammatory cytokine. When produced in response
to TNF-! production from macrophages IL-6 results in 
T-cell differentiation and assists T-cells in resisting apopto-
sis. Interleukin-6 production also results in the production
of CRP by hepatocytes and activation of the complement
system resulting in increased phagocytic activity of
immune cells. Besides these proinflammatory effects, IL-6
also has several powerful anti-inflammatory properties.
The release of IL-6 also results in an increase in the pro-
duction of IL-10, tumor necrosis factor soluble receptor,
and IL-1 receptor agonist, all of which assist in decreasing
the production of TNF-! and IL-1 and limit the proin-
flammatory cascade. More recent work has also demon-
strated that IL-6 can be produced by muscle in a TNF-!
independent manner. Repetitive muscle contraction results
in the production of IL-6 without an increase in TNF-!
(Figure 2). In fact, production of IL-6 via the TNF-!
 independent pathway actually suppresses the production
of TNF-! resulting in a powerful anti-inflammatory path-
way with exercise. The contradictory effects of IL-6 are
most likely due to the environment in which it is produced
and the presence or absence of TNF-!.
Systemically elevated inflammation in older adults is
particularly troublesome as it is one of the most important
physiological correlates of the frailty syndrome.8,9 Older
adults with chronic increases in proinflammatory cytokines
are more likely to suffer from a loss of lean tissue13 and
strength,13 and to experience mobility limitations and
 disability22 than those with lower levels of inflammation.
Moreover, several studies have demonstrated that older
adults with chronically elevated levels of inflammation are
at an increased risk of mortality.6,10,25 In a large study of
nondisabled older adults, Harris et al10 found that those
older individuals in the highest quartile for IL-6 serum
markers of inflammation were twice as likely to die in the
next 4 years than those individuals in the lowest quartile of
inflammation. Although increased levels of inflammatory
cytokines are associated with increasing age, chronic
inflammation may not be an obligatory manifestation of
aging per se. Evidence suggests that older individuals with
higher activity levels consistently show lower levels of both
systemic26-28 (as measured in the blood) and regional29 (as
measured in the muscle) inflammation. In addition, several
studies have demonstrated that aerobic training30-40 and
strength training41,42 can diminish chronic inflammation in
older adults. Because the positive inflammatory impact
resulting from increased physical activity and exercise are
integral components of physical therapy management in
older adults, an awareness of how chronic inflammation is
impacted by these variables is important.
The purpose of this narrative review is 3-fold. First, to
inform the physical therapist of the effects of aging and
increasing adiposity on chronic inflammation and the associ-
ation of inflammation with muscle loss, strength, and mobili-
ty impairments in older adults; and second, to review the cur-
rent evidence on the impact of physical activity levels and
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Figure 1. The inflammatory pathway. In the normal inflammation pathway, tissue injury or illness results in macrophage recruit-
ment and activation. Activation of macrophages leads to an increase in multiple proinflammatory cytokines including IL-6 that
increases T-cell differentiation and recruitment of further macrophages. Interleukin-6 also serves as an anti-inflammatory cytokine
recruiting other anti-inflammatory cytokines to bring an end to the inflammatory process. Chronic inflammation such that may
occur with aging and/or increasing fat mass results in excessive macrophage recruitment and activation leading to an abnormal
increase in proinflammatory cytokines. Because of currently unknown reasons, in chronic inflammation, the cytokines produced
by the anti-inflammatory pathway are unable to bring a halt to the inflammation, creating a positive feedback loop that facilitates
on-going inflammation.
Figure 2. Interleukin-6 production in the TNF-! independent
pathway. In the TNF-! independent pathway, contracting
myocytes during exercise produce IL-6 in the absence of
TNF-!. This leads to an increase in multiple anti-inflam-
matory cytokines and ultimately a decrease in proinflam-
matory cytokines such as TNF-! and IL-1.
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exercise on chronic inflammation in this population. Finally,
we will provide evidence-based clinical recommendations for
physical activity and exercise regimes with the aim of mitigat-
ing chronic inflammation in older adults. Literature targeted
for this narrative review included peer reviewed cross-section-
al, longitudinal, epidemiologic, and clinical studies in humans
and animals that were related to aging, adiposity, inflamma-
tion, mobility, strength, physical activity, and exercise.
AGING AND INFLAMMATION
The relationship of systemic inflammation with increasing
age is currently a hotly debated topic. Some have reported
consistent positive correlations between aging and inflam-
mation,43-49 though not all studies have found this to be the
case.50-53 It has been suggested that aging-related increases
in proinflammatory cytokines may be due to the presence of
multiple comorbidities,45,50 dysregulation of the immune
system,54-56 or an increase in adipose tissue.57 Multiple
studies have demonstrated an age-related increase in the
proinflammatory markers of IL-6, and CRP.43-49 Wei 
et al49, McKane et al47, and Hager et al46 have independ-
ently reported significant positive correlations between
serum IL-6 and age; this relationship also exists in nonhu-
mans.44 The caveat of most of these studies is that few took
into consideration the influence of disease state, comorbidi-
ties, and adipose tissue on the relationship between aging
and the specific inflammatory cytokines studied. Cartier 
et al and Ferrucci et al both found an initial positive rela-
tionship between aging and inflammation; however, further
 statistical analysis established that this relationship was
greatly blunted after accounting for the amount of visceral
adipose tissue43 or cardiovascular risk factors45, thus expos-
ing the possibility that it is comorbid disease conditions or
increases in adipose tissue rather than age itself that drives
these relationships. That is, the increase in proinflammatory
cytokines seen with aging may in fact be attributed to
underlying comorbidities such as cardiovascular disease or
increases in adipose tissue.
Further support for this assertion is found in both clini-
cal50 and epidemiologic45 evidence. Beharka et al50 screened
20 young and 26 older males for chronic disease or illness
prior to admission to their study and found no differences
in circulating serum IL-6 between the young and old sub-
jects. Because of the detailed screening process that was
used in this study and not reported by previous authors,
these findings suggest the possibility that previously report-
ed associations between age and chronic inflammation may
be at least in part attributed to the presence of underlying
disease. Ferrucci et al45 examined the relationship of proin-
flammatory cytokines with age in more than 1000 adults
aged 20 to 102 years. In both men and women, older age
was associated with increased circulating levels of IL-6 and
CRP; however, when these results were adjusted for the
presence of cardiovascular risk factors and of subclinical
cardiovascular disease, the relationships between IL-6 and
CRP with age, though still present, were much less robust.45
Collectively, these results suggest that although the contri-
bution of comorbid disease conditions to chronic inflam-
mation in older adults should not be ignored, there does
seem to be a degree of immune system dysregulation that
occurs with advancing age.
Dysregulation of the immune system in older adults has
been explored in multiple in vitro and in vivo studies. In
vitro studies of cytokine production have been equivocal, as
increased,58-63 unaltered,48,64 and decreased50,65,66 cytokine
production in older adults have been reported. Possible rea-
sons for these differences include the time points at which
cytokine production are measured, the types of cells stud-
ied, and the sex and health status of the participants. Fewer
studies have examined the effects of aging on dysregulation
of the immune system in vivo. When both young (20-27
years old) and older adults (61-69 years old) are given an
endotoxin injection of Escherichia coli, the older adults
consistently demonstrate a larger increase in body tempera-
ture and serum levels of TNF-!56 when compared to
younger individuals. Furthermore when examining both
young and older adults who have been diagnosed with an
acute pneumococcal infection older adults demonstrate an
increased and prolonged immune response with higher lev-
els of TNF-! and IL-6 than young infected and healthy age
matched controls up to 7 days postinfection,54,55 indicating
a prolonged inflammatory response and possible dysregu-
lation of the immune system. It has also been noted that
older adults with gastric cancer have higher levels of IL-6
postsurgery and that these levels fell more slowly than
younger patients with gastric cancer undergoing similar sur-
geries. Finally, Marik et al noted that the oldest patients
(those older than 85 years) admitted to the intensive care
unit for septic shock had the highest levels TNF-! on admis-
sion.67 That older adults, both in the presence of and in the
absence of disease, appear to have some level of immune sys-
tem dysregulation is well supported in the literature, though
the mechanism of this dysregulation is currently not well
established. Possible reasons theorized for the apparent dys-
regulation include decreased production of sex steroids,68
the presences of undiagnosed comorbidities such as athero-
sclerosis,45 and higher amounts of  adipose tissue.57
The increase in adipose tissue leading to immune system
dysregulation is an attractive hypothesis as excessive adi-
posity has also been mentioned as a potential mechanism
involved in age-related chronic inflammation.43,68 Excessive
fat mass and obesity are directly linked to increased levels
of the circulating proinflammatory cytokines TNF-!, IL-6,
and CRP in both the young69 and old.57,70 Studies have also
demonstrated a decrease in these same cytokines with
weight loss.69,70 Currently, it is thought that as adipocytes
increase in size with weight gain some adipocytes become
dysfunctional due to the increased presence of lipids in the
cell and local hypoxia within the adiopocyte.71 This combi-
nation of dysfunction and hypoxia leads to death of the
adipocyte. As adipocytes die macrophages are needed to
assist in clearing the dead cells. This increased presence of
macrophages leads to an increase of proinflammatory
cytokines and in a feed forward manner recruits additional
macrophages to the tissue, thus precipitating the increase
Journal of GERIATRIC Physical Therapy 3
Special Interest Papers
Copyright © 2011 The Section on Geriatrics of the American Physical Therapy Association. Unauthorized reproduction of this article is prohibited.
JPT200123_JGPT  29/09/11  7:49 PM  Page 3
14
in proinflammatory cytokines, leading to chronic inflam-
mation (Figure 3).71 Cesari et al have reported that both
CRP and IL-6 serum levels are positively associated both
with body mass index and with total fat mass in older
individuals.57 Taken together, this literature suggests that
age-related immune system dysregulation may stem from
increased body fat, a factor that has also been linked to
chronic systemic inflammation in older adults.
Although the precise mechanisms behind age-related
chronic inflammation are not fully understood, it does
appear that the rise in proinflammatory cytokines observed
with increasing age may result from of a combination of
inherent immune system dysregulation, the presence of
comorbid disease conditions, decreased physical activity,
and increased fat mass as individuals age. Regardless of the
cause, the relationships between chronic inflammation and
many of the negative consequences of aging cannot be
ignored. These consequences include but are not limited to
increased risk for a loss of muscle mass and strength,13
decreased mobility,25 and ultimately an increased risk of
frailty22,72 and mortality.6,10,25
MUSCLE MASS, STRENGTH, AND INFLAMMATION
Although normal aging is accompanied by a progressive
loss of muscle mass and force producing ability,73 large epi-
demiological studies have suggested that relative to those
with lower TNF-! and IL-6 levels, older adults with higher
levels are at increased risk of muscle impairments. In a
study of more than 3000 adults aged 70 to 79 years, Visser
et al13 reported that older adults with high levels of TNF-!
or IL-6 (defined as levels above the population median) had
smaller muscle area, lower appendicular muscle mass, and
decreased grip and knee extensor strength. These findings
were present even after statistically controlling for potential
confounding factors such as age, height, total body fat,
physical activity, health status, the use of anti-inflammato-
ry medications, and smoking. The results were even more
robust when looking at individuals who had increased levels
of both IL-6 and TNF-!. Using this same population of
individuals from the Health ABC study Schaap et al12 used
a multiple linear regression model to examine the effects of
increased IL-6 and TNF-! on thigh muscle cross-sectional
area as well as grip strength. Even after controlling for mul-
tiple covariates those individuals with the highest levels of
these proinflammatory cytokines experienced a decrease in
muscle cross-sectional area as well as grip strength over a 
5-year time period.12 Though the decrease in muscle cross-
sectional area was attenuated when accounting for weight
changes over the 5 years, a subanalysis of weight stable
individuals revealed that higher TNF-! was again associat-
ed with decreased thigh muscle area and grip strength.
Levinger et al74 recently reported that 19 older patients with
knee osteoarthritis had elevated levels in various inflamma-
tory cytokines including IL-6 within the quadriceps when
compared to age and body mass index–matched individuals
without osteoarthritis. Though they did not report the asso-
ciation between IL-6 and muscle strength, they did observe
a significant negative correlation (r"#0.37) between strength
and Monocyte chemotactic protein-1 (MCP-1), an inflam-
matory protein, whose expression is increased by the pres-
ence of TNF-! and IL-6.74
Chronic inflammation may be mechanistically linked to
muscle loss through the direct catabolic effects of TNF-!,
originally known as cachectin, due to its direct contribution
to catabolic muscle wasting in numerous inflammatory
conditions such as chronic obstructive pulmonary disease,75
chronic heart failure,76 human immunodeficiency virus,77
and cancer.78 Animal models, through injection and infu-
sion of TNF-! have revealed the direct catabolic effects of
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Figure 3. Increased inflammation with increasing adipose tissue. As an individual moves on the continuum between lean and
obese, lipids accumulate in adipocytes, causing the adipocytes to enlarge. Some enlarged adipocytes experience local
hypoxia from decreased access to the blood supply. The increased presence of lipids as well as local hypoxia leads to
death of enlarged adipocytes (apoptosis). As adipocytes die local proinflammatory cytokine levels increase (TNF-!, IL-6,
and CRP) to recruit macrophages to clear the dead adipocytes. The increased presence of macrophages leads to a further
increase in proinflammatory cytokines and recruits further macrophages resulting in chronic inflammation.
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increased levels of this proinflammatory cytokine. Mice,
rat, and canine models have all demonstrated a loss of
 muscle mass directly related to the increased presence of
TNF-!.23,79,80 The loss of muscle mass that occurs in the
presence of elevated TNF-! is most likely due to the multi-
factorial effect TNF-! has on muscle tissue. High levels of
TNF-! result in cell apopotosis,81 a decreased rate of pro-
tein synthesis, and an inhibition of myoblast differentia-
tion82 ultimately resulting in an impaired ability to increase
muscle mass. In a small study of 8 older frail adults, Greiwe
et al41 demonstrated that the rate of muscle protein synthesis
after 3 months of resistance training was inversely related
(r " #0.53) to TNF-! protein levels in the muscle. Tumor
necrosis factor-!may also inhibit muscle repair via apopto-
sis of muscle satellite cells83 resulting in a slow but progres-
sive loss of muscle mass over time as the muscle is unable to
repair itself from micro-injuries resulting in an overall
decline in muscle mass as one ages.
Solely attributing overall declines in muscle strength to
loss of muscle mass in older adults is inaccurate as the
aging-related loss of muscle mass explains as little as 5% of
the accompanying loss of muscle strength.84 Compounding
muscle atrophy in older adults is a decrease in the specific
force production of a muscle, defined as force produced per
cross-sectional area of the muscle fiber.85 Various factors
may contribute to this decrease in specific force production
including the slowing of muscle contractile properties and
rate of force development, reduced rate of cross-bridge
cycling, alterations in excitation-contraction coupling, and
changes in the muscle architectural properties. Although
age-related force production decline likely results from mul-
tiple factors including diminished physical activity, the
impact of chronic inflammation should not be ignored. The
presence of elevated levels of proinflammatory cytokines in
older adults may help to explain some of the diminished
force producing capability observed in this population.
Evidence supporting this assertion is found in animal
models that have revealed decreased muscle specific force
production only hours after a TNF-! injection.86 Of note,
this strength loss occurs prior to any loss of muscle mass,
indicating that an inflammatory milieu contributes to
impaired muscle force production in the absence of muscle
atrophy. Furthermore, a 12-week resistance training study of
frail elders with elevated baseline levels of TNF-! receptors
(another measure of TNF-! activity), reported that the num-
ber of TNF-! receptors is inversely correlated with muscle
strength gains.87 Those with the highest levels of TNF-!
receptors experienced the lowest strength gains with train-
ing, indicating that the gain in muscle strength may be neg-
atively influenced by the presence of high TNF-! levels.87
Strength decreases in the presence of increased levels of
TNF-! may be due to an interruption in the excitation-con-
traction coupling process.88-92 Where exactly this disruption
takes place is still under debate. The loss of strength may
also be due to the removal of actin and myosin proteins
resulting in an inhibition of the development of force even
prior to a loss of muscle mass.86,89 High levels of TNF-! also
decrease the resting membrane potential of the sarcolemma
and the cells ability to regulate calcium release from the sar-
coplasmic reticulum, both contributing to decreased force
production independent of any protein loss.88,91
Smaller clinical studies as well as larger epidemiological
studies support the hypothesis that chronic increases in
proinflammatory cytokines impair both strength and muscle
mass in older individuals. Although the mechanism behind
muscle mass and strength loss in the presence of increased
proinflammatory cytokines is still not clearly understood, it
does appear that increased levels of TNF-! in particular are
troublesome for older adults and may contribute to muscle
impairments in this population.
MOBILITY AND INFLAMMATION
The loss of muscle mass and strength in the presence of high
levels of proinflammatory cytokines may also partially
explain why increased levels of inflammation have consis-
tently been tied to decreased function and mobility in older
adults. Increased levels of TNF-!, IL-6, and CRP have been
linked to lower walking speed,25 poor physical function,93
a decreased ability to perform activities of daily living,22
and ultimately increased levels of disability and frailty.22,72
Large epidemiologic studies reveal that high levels of
proinflammatory cytokines increase the risk for developing
disability over 2 to 5 years.22,94,95 Ferrucci et al96 have
reported that individuals with the highest baseline levels of
IL-6 were also at the highest risk for the progression of dis-
ability and this could be at least partially explained by the
loss of muscle strength also associated with high levels of 
IL-6. These study findings were confirmed by Penninx et al94
in a study of almost 3000 adults aged 70 to 79 years. In this
investigation, those with the highest levels of TNF-!, IL-6,
and CRP at baseline were at the highest risk of developing
mobility limitations and disability over the next 30 months.
This relationship is consistent across comorbidities com-
mon in an aging population and across the aging spectrum.
Brinkley et al93 examined several separate populations
including those with chronic obstructive pulmonary disease
(COPD), congestive heart failure, self-reported disability, and
those at high risk for a cardiovascular event. They found that
across all disease conditions and comorbidities that increased
levels of serum CRP and IL-6 were associated with longer
times to complete the 4-m walk and lower short physical per-
formance battery scores.93 As well, across the aging spectrum
multiple studies of individuals aged 50 to more then 90 years
have reported that increased levels of proinflammatory
cytokines are related to decreased physical performance and
ability to perform activities of daily living.97 Tiainen et al97
demonstrated that in nearly 200 adults aged 90 years and
older increased serum levels of IL-6 and CRP were associat-
ed with a worse Barthel Index score, a 10-item measure of
ability to perform activities of daily living independently.
Though we cannot assign cause and effect, the literature
clearly identifies relationships between inflammation and
decreased muscle mass and strength, between inflammation
and impaired mobility and between decreased muscle mass
and impaired mobility in older individuals98 (Figure 4).
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Although speculative, it is intuitive that impaired mobility
would lead to sedentary behavior in turn creating the envi-
ronment for a self-perpetuating cycle of inflammation. In
this theoretical cycle, inflammation, decreased muscle size
and strength, and impaired mobility combine to create a
sedentary lifestyle that further compounds the proinflam-
matory adverse responses in a feed-forward fashion. In
summary, this underscores the important role of the physi-
cal therapist in minimizing mobility limitations in older




Physical activity may be a powerful countermeasure to
combat chronic inflammation and its deleterious effects in
older adults. Physical activity includes any body movement
produced by skeletal muscle that results in energy expen-
diture above resting basal levels and includes leisure time,
recreational, occupational, and transport activities.99 In
contrast, exercise is a subset of physical activity that is
planned repetitive movement with the object of improving
or maintaining fitness.99 Multiple epidemiological and
cross-sectional studies have demonstrated a strong inverse
relationship between levels of physical activity and mark-
ers of chronic inflammation across ages, body mass index-
es, and comorbidities.26-28,100,101 These relationships are
observed whether considering levels of proinflammatory
cytokines in the serum26-28,100,101 or in the muscle.29
Though these studies have consistently revealed an
inverse association between physical activity and chronic
inflammation, exercise intervention studies aimed at
reducing proinflammatory cytokine levels in older adults are
more variable. Although a majority of studies that employ
aerobic training,30-36,38-40 resistance training,41,42 or some
combination of the two37,102 suggest that exercise decreases
proinflammatory cytokines, some studies have not found this
to be the case.86,103-107 Of the resistance training studies86,103
that reported no statistical difference in proinflammatory
cytokines both reveal a trend for decreased IL-6 postinterven-
tion, thus, suggesting a lack of statistical power. Alternatively,
the inconsistent findings between studies may be explained by
the populations studied, and the time between the final exer-
cise bout and the postintervention measures. Most studies that
found no effect postexercise intervention do not report how
long postexercise intervention blood draws for serum inflam-
matory markers were conducted37,87,104,106 and in at least one
study blood draws were conducted as long as 2 weeks after
the completion of the intervention.107 Thompson et al39
demonstrated that while it takes 12 weeks to see significant
changes in serum markers of inflammation with exercise, it
only takes 2 weeks of detraining to see returns on almost base-
line levels.39 A prolonged time period between exercise inter-
vention and blood draws contributes to additional variability
in these investigations. Finally, study outcomes may differ
based on pretraining cytokine levels as individuals with the
highest levels of preexercise inflammatory markers usually
benefit the most from exercise.39
Consistent with the cross-sectional and epidemiologic
studies,26-28,100,101 those intervention studies reporting no
change in proinflammatory cytokines with exercise86,103-107
have employed serum markers. Two studies have demon-
strated that even in the presence of minimal change in
serum markers of inflammation with exercise, there may be
a very large change in the proinflammatory cytokines with-
in the muscle postexercise intervention.30,32 Gielen et al32
examined serum and muscle markers of inflammation in 
20 males with congestive heart failure pre- and post-6 months
of an aerobic exercise intervention. Patients in this study
exercised 20 minutes a day every day and additionally par-
ticipated in 1 hour a week of supervised group aerobic
training. Despite a significant decrease of more than 30% in
muscle-specific IL-6 and TNF-!, these authors reported no
change in serum inflammatory markers postexercise train-
ing. Lambert et al108 reported similar findings in a group of
obese frail older adults. After 12 weeks of exercise (90 min-
utes, 3 times per week of combined aerobic and resistance
exercise) the authors noted no decrease in serum IL-6 or
TNF-!. However, muscle biopsies showed a 50% decrease in
levels of IL-6 and TNF-! within the muscle tissue.108 Bruun
et al30 also examined the combined effects of 15 weeks of aer-
obic activity with a hypocaloric diet in 27 severely obese indi-
viduals. The aerobic intervention consisted of 2 to 3 hours of
moderate activity 5 days/week. At the end of 15 weeks, the
authors noted a significant decrease in serum measures of 
IL-6 and CRP but not in TNF-!. However, when examining
the muscle specific markers for IL-6 and TNF-!, large
decreases that exceeded those seen in serum were noted to be
more than 50% for IL-6 and 25% for TNF-!.
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Figure 4. Proinflammatory cycle. Established (solid lines)
and theorized (dashed lines) relationships were between
chronic inflammation, decreased muscle mass and strength,
impaired mobility, age, adiposity, and sedentary behavior.
Although speculative, impaired mobility may lead to seden-
tary behavior and increased adiposity in older adults that in
turn perpetuates a cycle of chronic inflammation.
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Decreased muscular expression of IL-6 in the absence of
serum level changes with exercise may be explained by the
influence of muscle contraction on the release of IL-6. As
noted previously, contracting muscle is able to produce 
IL-6 in a TNF-! independent pathway. The IL-6 produced by
contracting muscle is a powerful anti-inflammatory and, in
fact, can suppress the release of TNF-!. Three hours of
cycling can produce enough IL-6 in the muscle to suppress
the release of TNF-! even when an individual is injected with
an endotoxin.109 Repeated bouts of exercise such as those
employed by Gielen et al and Lambert et al would lead to
repeated release of IL-6 from the contracting muscle. This
“myokine” would then provide a powerful anti-inflammato-
ry environment within the muscle leading to overall decreas-
es in the release of proinflammatory cytokines within the
muscle tissue itself. (For a comprehensive review of this con-
cept the reader is encouraged to see reviews on this topic by
Pedersen et al110,111 for further details.) Overall exercise-
induced fat mass reduction provides another potential
hypothesis to explain proinflammatory cytokine decreases
observed with exercise. Several studies have suggested that
exercise, diet, or a combination of the 2 reduces adipose tis-
sue, an effect that may contribute to an overall reduction in
the proinflammatory cytokines that are released from
inflamed adipocytes.70,105,112 Although this may be an attrac-
tive hypothesis, the observation that at least 1 study has failed
to report decreased proinflammatory cytokines when only
weight loss is used independent of exercise,108 raises further
questions about fat mass as a potential mechanistic link
between exercise and chronic inflammation.
Regardless of the precise cause, there appears to be
strong evidence that both formal exercise30-42,102,105 and
simply increased levels of physical activity100 can have a
positive influence on chronic inflammation in older adults.
Furthermore, it is likely that the anti-inflammatory effects
of exercise are present in muscle even if no change is seen in
serum markers of inflammation.41,108 These findings pro-
vide yet another clear indication of the beneficial effects of
exercise and increased daily physical activity in this vulner-
able population.
CLINICAL RECOMMENDATIONS
Chronic increases in proinflammatory cytokines are asso-
ciated with a myriad of impairments and dysfunction in
older adults. Exercise is a potent preventive and interven-
tion strategy for chronic inflammation and appears to be
beneficial even in frail older adults.41 Exercise dosage that
has proven effective in decreasing proinflammatory
cytokines have ranged from a frequency of 2 to 5 days a
week and in daily duration from 20 minutes to 3 hours.
Exercise modes have included home walking programs,
treadmill walking, cycling, and resistance training using
machines and free weights. Aerobic exercise intensity has
varied between moderate walking and vigorous aerobic
activity at 80% of age–predicted maximum heart rate.
Resistance training has been reported effective utilizing 
8 to 10 exercises with 8 to 10 repetitions to target all major
muscle groups done 2 to 3 times per week at an intensity
of 65% to 80% of a one repetition maximum.41,42,102
Though exercise of any mode and duration may posi-
tively impact chronic inflammation, there is currently lim-
ited  literature to provide specific guidelines as to the most
effective mode and dose of exercise to decrease chronic
inflammation. Although further research is needed for the
most effective exercise prescription to target chronic
inflammation, the current American College of Sports
Medicine (ACSM) guidelines provide a reasonable  initial
approach with the aim of reducing chronic inflammation
and improving physical function in older adults. Exercise
to combat not only the proinflammatory cytokines but
also the deleterious effects that stem from them should
include a combination of aerobic and whole body resist-
ance training a minimum of 3 days a week for 30 to 60
minutes and the initial training program should last at least
12 weeks.37,39,102,113 Thompson et al39 demonstrated that
it takes at least 12 weeks to see changes in the serum levels
of IL-6 but only 2 weeks of detraining to return to baseline.
In addition, one long-term study examining the effects of
12 months of aerobic exercise on serum levels of IL-6
found that there was an additional decrease of serum IL-6
at 12 months compared with 6 months.37 These studies
underscore the importance of regular physical activity in
this population as positive changes in proinflammatory
cytokines may continue to take place weeks and months
after the initiation of exercise but may disappear in as 
little as 2 weeks after cessation of exercise.
Activation of large amounts of muscle mass are critical
to the muscular release of IL-6 from the TNF-! independ-
ent pathway, activities that engage large amounts of muscle
are most effective at producing IL-6 in this manner.111
Activities such as walking, running, biking, or using an
elliptical trainer would be advised. The addition of resist-
ance exercises 2 to 3 days a week targeting all major mus-
cle groups would also be beneficial to both decreasing the
proinflammatory cytokines41,42 as well as increasing muscle
protein synthesis.41
As physical therapists see a larger proportion of older
adults who suffer the functional consequences of frailty,
there is an increasing interest in how best to address the
treatment and prevention of this debilitating syndrome.
Chronic inflammation is one of the strongest correlates of
the frailty syndrome and can lead to a myriad of problems
including muscle and strength loss and mobility limitations.
Physical activity is a powerful anti-inflammatory tool that
physical therapists can use not only to combat the effects of
chronic inflammation but also to combat the production of
proinflammatory cytokines. Exercise and increased physical
activity can provide an anti-inflammatory environment
within the muscle that may mitigate many of the effects of
chronic inflammation on muscle. Future research should
focus on the causes of chronic inflammation as well as the
most effective treatments and exercise regimes to decrease
inflammation.
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CHAPTER 3
INFLAMMATION, INTRAMUSCULAR FAT AND MUSCLE 
AND MOBILITY FUNCTION DIFFERENCES 
BETWEEN HEALTHY AND FRAIL
 OLDER ADULTS
Introduction
Sarcopenia, a loss of lean muscle mass, has traditionally been identified as a 
major reason for a loss of muscle and mobility function in older adults,1-4 however, recent 
research has documented a clear disassociation between the loss of lean muscle mass and 
function in older adults.5-8  Intramuscular adipose tissue (IMAT), an ectopic fat depot 
found beneath the deep fascia of the thigh, is increasingly recognized as a negative 
predictor of both muscle and mobility function in older adults and presents a potential 
link between the two. 
Increased levels of IMAT have been associated with decreased strength and 
mobility and correlated with an increased risk of mobility limitations in older adults.9-11 
Because of this, increased levels of IMAT may be an unwanted but inevitable 
consequence of aging, even in individuals who lose weight over years.5 Increased activity  
levels, however, may actually blunt or eliminate this age-related increase in IMAT.12,13   
Master athletes demonstrate no differences in the levels of IMAT across 10 year age 
groups 40-49,50-59, 60-69 and 70 and older (mean age 60.1 years) reinforcing the notion 
that increases in IMAT are not inevitable with aging but are likely related to factors such 
as muscle disuse and disease. Whether a high level of IMAT is merely a marker of muscle 
dysfunction in older inactive individuals, or if it plays a more active role in muscle and 
mobility dysfunction, remains unknown. 
The mechanism underlying IMAT’s negative influence is currently unknown but 
has been speculated that like other ectopic fat depots it may involve an inflammatory 
pathway.5, 14-17 Excessive fat mass has been directly implicated in increased circulating 
levels of numerous proinflammatory cytokines such as tumor necrosis factor alpha (TNF-
a), interleukin-6 (IL-6), and C-reactive protein (CRP) in both young and old individuals.
14, 18-21  Increased levels of visceral adipose tissue, also an ectopic fat depot, directly 
contribute to the increase in circulating proinflammatory cytokines.19
TNF-a, IL-6 and CRP basal circulating levels have all been shown to be closely 
associated with muscle and mobility function in older adults.22-26 However few studies 
have examined the effect of increased levels of inflammation in locomotor muscle of 
older adults. Higher systemic levels of proinflammatory cytokines in serum are 
associated with decreased strength and mobility in older adults22-26 and increased 
circulating levels of proinflammatory cytokines result in cell apoptosis,27 a decreased rate 
of protein synthesis,28 and decreased muscle quality29, all of which may contribute to 
decreased strength and mobility in older adults.30  Several studies on the effects of 
increased systemic levels of circulating proinflammatory cytokines show a relationship 
22
between inflammation and muscle and mobility function,22, 23, 26, 31, 32 however, no study 
to date has looked at relationship of inflammation, muscle and mobility function in the 
muscle of older adults.  
In order to clarify if IMAT is a by-product of age per se or if it is related to 
inactivity the primary aim of this study was to compare muscle and mobility function, 
IMAT and muscular inflammation in age and BMI matched older frail and nonfrail 
adults.  A secondary aim was to examine the relationship of IMAT, muscular 
inflammation, muscle function, and mobility in older frail and nonfrail adults. We 
hypothesized that IMAT would be related to inactivity rather then aging and that older 
frail adults would have decreased muscle and mobility function and higher levels of 
IMAT and muscular inflammation when compared to nonfrail adults.  We further 
hypothesized that a relationship between muscle and mobility function, IMAT and 
muscular inflammation exists in this group of older adults. 
Methods
Participants
An accessible population of older adults in our local community was recruited 
using local health care clinics, newspaper ads, target mailings, church groups, senior 
centers, and health fairs. To maximize potential differences in IMAT, two groups of older 
non-obese adults (a frail sedentary and a nonfrail active group) were recruited. Due to the 
difficulty in finding and recruiting frail individuals we planned on recruiting twice as 
many healthy individuals and sought to power this study based on our primary aim of 
23
determining differences in IMAT, muscle and mobility function and inflammation 
between frail and nonfrail individuals.  Based on prior studies effects sizes of 1.36 to 2.39 
for differences between active and sedentary adults we estimated that we would need 
between 5 and 12 nonfrail individuals and 3 to 6 frail individuals.33, 34 We conservatively 
aimed to enroll at a minimum 12 active individuals and 5 frail individuals.  Inclusion 
criteria for both groups included individuals over the age of 65 years and a BMI of less 
then 30. Additionally the sedentary frail group was required to be classified as at least 
moderately frail by a modified physical performance test (MPPT) score of < 25 and 
reported little to no planned physical activity over the last 12 months.35-37 The active 
nonfrail group was made up of individuals who had MPPT scores of > 32 and reported at 
least 90 minutes of moderate activity a week over the last year.35-37 Exclusion criteria for 
both groups included diabetes, COPD, active cancer, chronic heart failure, or chronic 
infection. Additionally a subgroup of participants were asked to undergo a percutaneous a 
muscle biopsy if they were free from heart disease or any other condition known to 
increase systemic inflammatory levels.  Participants in this subgroup were also excluded 
if they were using any medication known to influence inflammation such as tobacco 
products, corticosteroids, nonsteroidal anti-inflammatories, hormone replacements or 
anticoagulants.  Any individuals in this subgroup who were on statin medications were 
asked to hold all statin medication for at least 7 days prior to the muscle biopsy. Figure 
3.1 demonstrates the recruitment flow from initial contact to recruitment for a muscle 
biopsy. 
24
Figure 3.1 Recruitment and Consort Diagram
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Study Design 
Potential participants completed a telephone screen followed by an in person 
screen to determine eligibility. During the in person screen the modified physical 
performance test was performed and scored by a physical therapist to ensure the 
participants met the requisite scores.37 Prior to all screening tests, all eligible volunteers 
signed an institution approved consent form.  Immediately after the in-person screening, 
demographic data were gathered from the participants and their first clinic testing visit 
was scheduled within 2 weeks.  During the first clinic testing session, individuals 
underwent functional testing to determine mobility, strength testing to determine muscle 
function, and an MRI of their legs to determine the cross sectional area of lean muscle 
mass and IMAT.  Within 1 week of functional testing individuals who met the inclusion 
criteria for a muscle biopsy underwent a muscle biopsy to determine levels of local 
inflammation within the muscle.  
Muscle Function Testing
  Muscle function was operationally defined in this study as maximum knee 
extension voluntary strength. A tester blinded to group assignment collected muscle force 
production via knee extension strength in both legs. Knee extension strength was 
determined via a maximum voluntary isometric contraction (MVIC) on a KinCom 
dynamometer (Chattanooga Inc., Hixon, TN) as follows: participants were stabilized by 
chest and thigh straps and seated with their knees fixed at 60 degrees of flexion with their 
arms folded across their chest. Prior to testing, participants practiced submaximal 
contractions at 50 and 75% of their perceived maximal effort prior to one practice 
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maximal contraction trial. After a 2 minute rest period, three separate maximal 
contractions were performed. Each maximal contraction was held for 5 seconds with a 3 
minute rest between trials. The outcome variable muscle force was calculated as the 
average force of three trials. The order of testing (right versus left) was randomized 
among subjects.38 This test has been shown to have a high degree of reliability (ICC=.
99).39
Mobility Function Testing 
A tester blinded to group collected all mobility testing measures. Mobility was 
determined using three tests: (1) a six-minute walk (6MW), (2) stair ascent (StairA) and 
(3) self-selected gait speed (GS). These performance tests were chosen to represent 
mobility function and have been shown to be both valid and reliable in this population.
40-42 The 6MW test, a measure of the distance a subject walks in 6 minutes, was used to 
assess overall mobility. Participants were asked to cover as much distance as possible in 
six minutes without running. Distance was recorded in meters. The stair A test required 
participants to ascend one flight of stairs under close or contact supervision as quickly 
and safely as possible. Time was recorded to the nearest 0.01 second from a verbal go 
signal to final foot placement on a standard flight of 10 stairs, and the average of three 
trials was recorded. Self-selected gait speed was measured over a 50 foot course.  
Individuals were instructed to walk at a comfortable pace starting at the word “go.”  They 
were asked to walk out 25 feet and back. Timing took place from the command “go” until 
the starting line was crossed on the way back.37, 43 Participants were allowed to use any 
walking aid they used on a daily basis.  All instructions, encouragement and 
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measurements for all functional tests were carried out in a consistent manner according to 
standardized instructions. 
Lean Muscle Mass and IMAT Determination
 MRI methods for determination of lean muscle mass and IMAT have been 
described in detail elsewhere.38 Briefly bilateral magnetic resonance imaging (MRI) 
scans of the thighs were obtained. The respective IMAT and lean tissue cross sectional 
areas were calculated from the MRI scans. Subjects were placed supine in a 3.0 Tesla 
whole body MR imager (Siemens Trio, Siemens Medical, Erlangen, Germany). The legs 
were scanned in a coronal plane and the midpoint of the thigh was determined and 
defined as half way between the superior margin of the femoral head and the inferior 
margin of the femoral condyles. Axial imaging (5mm thick slices at 1 cm intervals) of the 
legs was then performed over 1/2 the length of the femur, centered at the midpoint of the 
thigh. Separate fat and water images were created with custom software using the three-
point Dixon method. A tissue model was then used to calculate estimates of total fat and 
nonfat volume fractions on a per pixel basis, which were displayed in image form. All 
sequences were performed with a phase array torso/abdomen coil.  Eleven images from 
the middle 1/3 of each thigh were used to determine average cross-sectional area (cm2) of 
IMAT and lean tissue. Manual tracing eliminated subcutaneous fat and bone and isolated 
the fascial border of the thigh to create a subfascial region of interest (ROI). Total IMAT 
and lean tissue were calculated by summing the value of percent fat fraction and percent 
lean tissue fraction over all pixels within the ROI using custom written image analysis 
software (MATLAB; The MathWorks, Natick, Massachusetts). This sum was multiplied 
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by the area of each pixel to give total fat and lean tissue CSAs within the ROI. This 
method accurately measures fat and lean tissue in pixels that contain both by allowing 
fractional contributions to the fat and lean tissue CSA calculations.44 This allows 
microscopic fat within muscle tissue as well as thin planes of fat adjacent to fascial 
planes to be accurately taken into account, even when image resolution is inadequate to 
delineate these visually. The same investigator, blinded to time point of the scan and slice 
location, performed measurements of individual participants. This technique has 
demonstrated high levels of intrarater reliability,45 test-retest reliability,46, 47 and 
concurrent validity when compared to imaging of a cadaveric phantom limb.45  To 
normalize IMAT for thigh size the percent of IMAT was calculated for each individual.  
This was calculated by dividing the cm2 of IMAT by the cm2 of the thigh excluding 
subcutaneous adipose tissue and bone. 
Muscle Biopsy 
All muscle biopsies in eligible participants were performed within one week of 
functional testing.  Participants were asked to refrain from any strenuous activity within 
48 hours of the muscle biopsy. All individuals presented in the morning after a 12 hour 
fast for a percutaneous needle biopsy.48, 49 The skin and fascia 12-15 cm above the lateral 
joint space was anesthetized with 5cc of 1% lidocaine and a small incision was made.  
The biopsy needle was inserted 3-5 cm beyond the fascia into muscle and 3 passes (bites) 
made to yield approximately 200 mg of muscle tissue.  Following biopsy, deep pressure 
was applied for 20 minutes, followed by a steri-strip bandage and pressure dressing.  The 
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sample obtained was dissected free from blood and visible fat, snap frozen in liquid 
nitrogen and stored at -80 C until analysis.  
Proinflammatory Cytokines Measures in the Muscle
 IL-6 and TNF-a were the dependent variables chosen to represent 
proinflammatory cytokines levels within the muscle.  In order to measure the expression 
of these proinflammatory cytokines within the muscle both mRNA and protein 
expression of IL-6 and TNF-a were measured. To determine the mRNA expression of 
IL-6 and TNF-a in the muscle tissue of the participants total RNA, cDNA synthesis and 
real time qPCR were conducted as previously reported.50  Total RNA was extracted by 
homogenizing 15-20 mg muscle tissue with a handheld homogenizing dispenser 
(PowerGen 125; Fisher Scientific) in a solution containing 0.75 ml Tri reagent (LS; 
Molecular Research Center, Cincinnati, OH) and 0.25 ml nuclease free water. The RNA 
was separated into an aqueous phase using 0.2 ml of chloroform and precipitated using 
0.5 ml of isopropanol. Isolated RNA was washed with 1 ml of 75% ethanol, dried, and 
then suspended in a known amount of nuclease-free water (1.5 ml/mg tissue). RNA was 
DNase-treated using a commercially available kit (TURBO DNase-free, Life 
Technologies, Carlsbad, CA). RNA concentration was determined with a NanoDrop 2000 
(ThermoFisher Scientific, Waltham, MA). Afterwards, 0.5 mg of total RNA was reverse 
transcribed into cDNA according to the manufacturers’ directions (iScript, BioRad, 
Hercules, CA). All isolated RNA and cDNA samples were stored at -80°C until analyzed. 
Real-time qPCR was carried out with an Applied Biosystems 7900HT fast sequence 
detection system. Taqman predesigned primers (IL-6 and TNF-a) were purchased from 
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Life Technologies. Values were normalized to beta 2-microglobulin then fold change 
values were calculated using the 2-∆∆Ct method.51  
 To determine protein expression of IL-6 and TNF-a in the muscle western blots 
were used.  Frozen muscle tissue was homogenized in a buffer cocktail with protease 
inhibitors in a prechilled glass tube under ice. Muscle homogenates were centrifuged at 
6000 rpm for 10 minutes at 4°C and the supernatant was subsequently collected and 
transferred to a new microcentrifuge tube. Total protein concentration for each sample 
was determined on a spectrophotometer using a colorimetric protein assay (Bio-Rad; 
Bradford) and an albumin standard curve. Whole muscle homogenates were diluted 1:1 in 
a 2X sample buffer. Homogenates were loaded at equal protein concentration on a 
Criterion Tris-HCL precast polyacrylamide gel (Bio-Rad) and subjected to SDS-PAGE 
(150V) for 1h in running buffer. Each gel contained alternating Healthy and Frail samples 
loaded in duplicate, and a molecular weight ladder.  An internal control was loaded in 
duplicate on each gel for band normalization and comparisons across blots. Protein was 
transferred (50V; 1h) to a polyvinylidene diflouride membrane in ice cold transfer buffer 
then blocked for 1h at room temperature with 2% nonfat dry milk (NFDM) in Tris-
buffered saline in 0.1% Tween-20 (TBST). Membranes were incubated overnight in 
primary antibody diluted in 2% NFDM in TBS. The next morning, blots were rinsed in 
TBST for 5 minutes, rocked in secondary antibody for 1h at room temperature in 2% 
NFDM in TBS then serially washed (15 minutes, 4 x 5 minutes) in TBST.  
Chemiluminescence reagent (ECL Plus, GE Healthcare) was applied to each blot for 5 
minutes. Optical density measurements were obtained with a digital imager (Bio-Rad). 
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Membranes were stripped (Restore PLUS, Thermo Scientific) of primary and secondary 
antibodies then reprobed for a-tubulin (1:50,000; Sigma Aldrich, St. Louis, MO). 
Densitometric analysis was performed using Quantity One software (Bio-Rad).  After 
subtracting out background, all western blot data were normalized to the internal control 
and replicate samples were averaged. The following antibodies were used in this 
experiment: IL-6 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA), TNF-a (1:500; 
Cell Signaling, Boston, MA), and Toll-like receptor 4 (1:500; Santa Cruz Biotechnology). 
Donkey anti-rabbit and goat anti-mouse IgG horseradish peroxidase-conjugated 
secondary antibodies (1:6000) were purchased from Santa Cruz Biotechnology.  
Data Analysis.
 Data were analyzed with SPSS Statistics 20.0 (SPSS, Chicago, IL). Descriptive 
statistics were calculated for demographic variables and dependent measures. 
 Aim One: Comparing Muscle and Mobility Function, IMAT and Muscular 
Inflammation. For our first aim of comparing muscle and mobility function, IMAT and 
muscular inflammation in age and BMI matched older frail and nonfrail adults 
independent t-tests were used. The independent variable was group (frail or nonfrail) and 
the dependent variables were percent IMAT, mRNA and protein expression for IL-6 and 
TNF-a, and all mobility and strength measures.  
 Aim Two: The Relationship of IMAT, Muscular Inflammation and Muscle and 
Mobility Function. For our second aim of examining the relationship of relationship of 
IMAT, muscular inflammation, muscle function, and mobility in older frail and nonfrail 
adults pearson product correlations were used.  Using these correlations we examined the 
32
relationship of percent IMAT, mRNA expression of IL-6 and TNF-a with all mobility 
(6MW, SA, GS) and MVIC in both groups. The level of significance was set at P<.05 and 
a bonforonni correction was used for multiple comparison. 
Results
Participant Characteristics
A total of 26 individuals were enrolled in the study.  In accordance with our a 
priori power calculation 18 nonfrail and 8 frail individuals were enrolled.  A subgroup of 
7 frail and 12 nonfrail individuals met the inclusion criteria for a muscle biopsy.  During 
the MRI, suspected cancer was found in one nonfrail individual and they were eliminated 
from the study. Additionally one non-frail individual refused the MRI and was thus 
eliminated from the study. All remaining individuals completed all testing procedures for 
the study resulting in data for 16 nonfrail and 8 frail completed the study. The 
demographics for both groups of participants are summarized in Table 3.1.
Table 3.1  Participant characteristics
 Frail Healthy
N 8 16
Age (years) 83.3 (4.5) 78.1 (5.7)
BMI (Kg/m2) 25.0 (3.3) 23.9 (2.6)
MPPT test 16.3 (7.7) 35.2 (1.2)
% Lean 82.0 (4.9) 88.3 (2.0)
% IMAT 18.0 (4.9) 11.7 (2.0)
Mean [± SD]; BMI = Body Mass Index; MPPT = modified physical performance test 
score; % lean= percentage of thigh lean tissue average cross sectional area as measured 
with MRI excluding subcutaneous fat and bone in the biopsied leg; %IMAT= percentage 
thigh intramuscular adipose tissue average cross sectional area as measured with MRI 
excluding subcutaneous fat and bone in the biopsied leg. 
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 Aim One: Comparing Muscle and Mobility Function, IMAT and Muscular 
Inflammation. Significant differences were found between the frail and nonfrail groups 
for all mobility and muscle function measures. The frail group was found to cover less 
distance on the 6MW  (p<.001), took more time to complete SA (p=.03), and had a 
slower self-selected GS (p=.002).  The frail group was also significantly weaker MVIC 
(p=.03).  Despite having similar ages and BMI’s, significant differences between the frail 
and nonfrail group was also found for the % lean and the % IMAT in the thigh.  The frail 
group was noted have less lean tissue mass (p=.004) and more IMAT (p=.004) than the 
nonfrail group. Table 3.2 demonstrates the means for all muscle and mobility measures 
collected for both the frail and healthy groups. 
Table 3.2 Differences between frail and healthy older adults for muscle and mobility data 
Frail Healthy
6MW (meters) 278.50 (147.6) 540.81 (77.9)*
SA (sec) 29.0(25.9) 4.26 (.9)*
GS (m/sec) .67(.21) 1.23 (.3)*
MVIC (N) 161.9 (49.6) 323.1(121.4)*
% IMAT 18.02 (4.9) 11.6 (2.0)*
% Lean 82.0 (4.9) 88.3 (2.0)*
6MW=distance in meters covered in 6 minute walk test test; SA=time in seconds to 
ascend one flight of stairs; GS=self selected gait speed in meters/second; MVIC= 
maximal voluntary isometric contraction of knee extensor muscles in Newtons; % 
IMAT= percentage of IMAT in thigh; % lean = percentage of lean tissue in the thigh. 
*significant difference between groups. (P<.05)
. 
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In the subgroup analysis the mRNA(p=.015) and protein expression (p= .016) of 
IL-6 was significantly higher in the frail group then the nonfrail group (p=.015) as seen in 
Figure 3.2 A and B. There was no difference found in the mRNA (p= .132) or protein 
expression (p= .265) for TNF-a between the groups as seen in Figure 3.2 C and D. 
 Aim Two: The Relationship of IMAT, Muscular Inflammation and Muscle and 
Mobility Function. Intramuscular adipose tissue was strongly correlated with mobility 
and muscle function.  Percent IMAT in the thigh was significantly correlated with 
distance covered in the 6MW (r=-0.726, p<.001), SA (r=0.699, p=.001), self-selected GS 
(r=-0.676, p=.001), and MVIC (r=-.752, p<.001).  A significant positive correlation 
(r=0.565 p=.009) was found between the % IMAT in the thigh skeletal muscle expression 
of IL-6 mRNA. IL-6 mRNA expression was also significantly correlated with 6MW 
(r=-0.685, p=.001) and self-selected GS (r=-0.617, p=.004). While SA was significantly 
correlated with (r=0.535 p=.013) IL-6 mRNA expression after the bonforoni correction 
this was no longer statistically significant.  IL-6 mRNA expression was also moderately 
correlated with MVIC (r=-0.370) but it did not reach the level of significance (p=.072). 
IL-6 protein expression was significantly correlated with self-selected gait speed (r=-.70, 
p=.001) and MVIC (r=-.549, p=.009) but was not significantly correlated with 6MW (r=-.
540, p=.01) after the bonforoni correction.  There was also no significant correlation 
between IL-6 protein expression and % IMAT (r=.252, p=.157) No significant 
correlations (r ranged .023 to .163, p values ranged  from .153 to .465) were found for 
TNF-a mRNA or protein expression with any mobility, MVIC, or % IMAT.   
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Figure 3.2 IL-6 mRNA and Protein Expression in Muscle of Healthy vs Frail Adults. 
Mean expression of (A) IL-6 mRNA, (B) IL-6 protein and (C) TNF-a mRNA and (D) 
TNF-a protein in the vastus lateralis of healthy and frail older adults. * Statistically 
significant differences between healthy and frail adults (P<0.05).
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Figure 3.2 Continued 
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Discussion
 This study is the first study that we are aware of that examines the relationships of 
IMAT and inflammation in aging muscle tissue. Our primary aim was to clarify if IMAT 
was a by-product of age or related to inactivity by comparing muscle and mobility 
function, IMAT and muscular inflammation in age and BMI matched older frail and non-
frail individuals. To better understand the potential harmful nature of IMAT our 
secondary aim was to examine the relationships of IMAT, inflammation, and muscle and 
mobility function in older adults. As hypothesized, we found that IMAT was related to 
inactivity rather then aging and that older frail adults had both increased levels of IMAT 
and inflammation when compared to nonfrail adults. We also found significant 
relationships between IMAT, inflammation, and muscle and mobility function in this 
group of older adults. 
IMAT: Aging or Inactivity
 The novel findings in this study were that significant differences in both IMAT 
and the mRNA and protein expression of IL-6 exist within the muscle of frail and non-
frail older adults with vast difference in muscle and mobility function. We found these 
differences in levels of IMAT despite similar ages and BMI’s in the frail and non-frail 
groups of older adults. While it has been previously suggested that increased levels of 
IMAT were an inevitable consequence of aging our findings would suggest that increased 
IMAT may be more an effect of inactivity and illness then aging.5 There are differing 
results in the literature regarding this questions, Delmonico et al. found in a 5-year 
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longitudinal study that IMAT levels increased even in individuals who lost weight.5 
However, more recently Wroblewski et al. reported in a cross-sectional study of master 
athletes ages 40 to 70 plus years that IMAT levels did not increase significantly with 
age.13  Further support of the inactivity hypothesis was found by Manini et al. who 
demonstrated increased IMAT levels in the thigh and calf of young (19-28 years old) 
individuals after 30 days of single limb suspension. IMAT volume increased up to 20% in 
the lower extremity suggesting that even in young healthy individuals increased IMAT is 
a consequence of decreased activity levels. 
Taken together, along with our findings, these studies would suggest that 
increased IMAT levels may be more of a product of illness and disuse then age per se.  
While we did not have a younger group of individuals to compare with, our data suggests 
that IMAT differences exist between frail and nonfrail older adults of similar age ranges.  
If increases in IMAT were solely an age related phenomenon we would expect to see 
similar levels of IMAT in our frail and nonfrail individuals.  The suggestion that IMAT 
may be related to activity rather then aging per se is important as physical activity may be 
a treatment to ameliorate or even decrease the increased levels of IMAT found in older 
frail adults.  
Inflammation: Aging or Inactivity
Surprisingly little research has examined the inflammatory state of skeletal 
muscle in older adults.52 While previous studies have compared muscular IL-6 mRNA 
and protein expression in older healthy adults and young healthy individuals,53-56 or 
changes in muscular inflammation pre- and post-chronic exercise,33, 57, 58 this is the first 
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study that we are aware of that compares mRNA and protein expression of IL-6 and TNF-
a in the muscle of frail and nonfrail older adults of similar ages and BMI’s.  Our results 
suggest that differences in IL-6 mRNA and protein expression exist in the muscle 
between older frail and nonfrail individuals.  Previous research has found little to no 
difference in IL-6 mRNA expression in the muscle of young healthy versus older healthy 
adults.53-56 Findings have also been equivocal on the effect of aging on TNF-mRNA 
expression in muscle with some studies finding increases compared to younger 
individuals59 and some studies finding no differences compared to younger individuals.53, 
56, 60  In the current study we found no differences in the muscular expression of TNF-a 
mRNA between frail and nonfrail older adults.  It is known that TNF-a release is more 
variable then IL-6 and this may be one reason why we did not find any differences 
between frail and nonfrail individuals.61 It is also possible that with our small sample size 
we were underpowered to detect differences between frail and nonfrail individuals with 
regards to TNF-a.  
IMAT, Inflammation and Muscle and Mobility Function
There is some speculation that the negative consequences of IMAT on muscle and 
mobility function may be from the release of pro-inflammatory cytokines that act in a 
paracrine like manner on nearby muscle tissue.5, 14-17  Our results suggest that levels of 
muscular inflammation may relate to levels of IMAT within the muscle as we found a 
moderate significant correlation between levels of IMAT and levels of IL-6 mRNA within 
the muscle although we did not find a relationship between IMAT and protein expression 
of IL-6. It is possible with our small data set that we were underpowered to see any 
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relationship between IL-6 protein and IMAT.  We also found moderate significant 
correlations between most measures of muscle and mobility function with IMAT and 
IL-6 mRNA and protein expression. It has been well documented that increased serum 
levels of IL-6 are closely associated with decreased muscle24, 26 and mobility23, 62, 63 
function in older adults and multiple studies have demonstrated that even after controlling 
for total body fat, physical activity and health status, individuals with the highest 
circulating levels of pro-inflammatory cytokines have the lowest levels of strength and 
mobility.22-26 We did not, however, find any relationship between gene or protein 
expression of TNF-a and IMAT.  Nor did we find any relationship between TNF-a 
mRNA or protein expression with any measures of muscle of mobility function. 
Limitations and Directions for Future Research 
 This study included a small number of individuals and thus our results should be 
interpreted with caution.  Because individuals with disease processes that are known to 
increase inflammatory levels were purposely excluded from our muscle biopsy analysis, 
our findings are likely conservative. Gene expression of local inflammatory cytokines in 
the muscle of older adults may be even more robust if including individuals with diseases 
typically associated with increases in both IMAT and inflammation such as diabetes.  
While we did attempt to control for multiple co-morbidities and used a careful screening 
process to do this, it is also possible that individuals with higher inflammatory levels had 
undiagnosed co-morbidities that we were not aware of.  We also recognize the slight age 
discrepancy between our groups of frail and non-frail individuals.  While the age 
difference of 5.2 years is small it is possible that the reason for our findings was the age 
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difference.  However given that multiple previous research studies demonstrate no 
significant differences between IL-6 mRNA expression in young and old healthy 
individuals this is unlikely.53-56      
Clinical Relevance
 This study is the first to examine the relationship of IMAT and inflammation in 
aging muscle tissue and may expose new ways in which physical activity can stave off 
the negative consequences of aging on skeletal muscle. Increased levels of IMAT and 
IL-6 mRNA and protein expression are both related to muscle and mobility function in 
older adults.  It also appears that a significant relationship exists between IMAT and IL-6 
mRNA expression. This IMAT-inflammatory pathway provides a potential mechanism 
behind IMATs negative influence on muscle and mobility function and is a potential 
reason for the harmful effects of IMAT on skeletal muscle.  Additional studies are needed 
to more clearly delineate the relationship between IMAT and inflammation in older adults 
and to explore the relationship between systemic inflammation, muscular inflammation 
and IMAT.
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CHAPTER 4
RELATIONSHIP OF ECTOPIC FAT DEPOTS AND INFLAMMATION
IN THE MUSCLE OF OLDER FEMALES
Introduction
Over the last 20 years there has been a rapid expansion in our understanding of 
adipose tissue.  Once thought to be a passive storage depot for excess calories, important 
only to energy homeostasis, we now know that adipose tissue is capable of expressing 
and secreting a multitude of hormones and chemicals that travel throughout the body to 
act in an autocrine, paracrine, and endocrine manner signaling the heart, musculoskeletal, 
central nervous and metabolic systems.1-3 Specifically, the release of pro-inflammatory 
cytokines from adipose tissue, such as tumor necrosis factor-a (TNF-a), interleukin-6 
(IL-6), and c-reactive protein (CRP) are important initiators of chronic inflammation,1, 4 a 
process that has been implicated in the pathogenesis of a multitude of diseases including 
type 2 diabetes, cardiovascular and cerebrovascular disease, and dementia.5-9 High levels 
of circulating pro-inflammatory cytokines in older individuals are also associated with 
increased mortality risk,10 sarcopenia,11, 12 reduced muscle strength,13 and decreased 
mobility.14, 15 
Recent studies have suggested that the location of adipose tissue rather than 
simply total body adiposity, may be important in the systemic increase of circulating pro-
inflammatory cytokines.16-19  In particular visceral adipose tissue (VAT) has a positive 
relationship with levels of TNF-a, IL-6 and CRP,16, 18-20 and the extraction of VAT leads to 
a decrease in circulating pro-inflammatory cytokines.21, 22 Multiple studies have also 
demonstrated a decrease in pro-inflammatory cytokines with diet and exercise- induced 
weight loss23, 24 and with physical activity.25-28 
Advancing age results in a redistribution of fat depots, despite stable or 
decreasing overall fat amounts, with adipose storage sites changing from subcutaneous 
locations to the more harmful VAT or ectopic fat depots in the liver and muscle.3, 29-31  
Specifically, intramuscular adipose tissue (IMAT) may also influence the pro-
inflammatory milieu, similar to VAT, as positive associations between circulating levels 
of IL-6 and IMAT in locomotor muscle of older adults have been noted.16 In addition to 
its potential inflammatory contribution, IMAT has been associated with muscle weakness 
and mobility impairment32-35 and, importantly to risk of future mobility limitation in older 
adults.34, 35 It has been theorized that increased IMAT is a normal consequence of aging 
36; however, more recent evidence suggests that increased IMAT may be more a product 
of inactivity then age per se and therefore may be modifiable.37-39
Multiple authors have suggested16, 36, 37, 40, 41 that IMAT’s negative relationship 
with muscle and mobility function may be attributed to the release of pro-inflammatory 
cytokines; to date this relationship has not been clarified. The independent parallels 
between inflammation and IMAT, with strength and mobility loss in older individuals, 
may in fact be linked to the release of inflammatory cytokines from IMAT.  IMAT has 
been associated with systemic circulating levels of IL-6, though no study to our 
knowledge has examined the relationship of IMAT with local muscle concentrations of 
50
pro-inflammatory cytokines within the locomotor muscle. The role of IMAT and it’s 
inflammatory contribution to muscle is important as it may provide new therapeutic 
targets for combating muscle and mobility impairments often seen in older adults. 
Despite our knowledge of the influence of VAT and IMAT on circulating cytokines much 
less is known about the influence of these ectopic fat depots on local levels of cytokines. 
Therefore, the purpose of this study was to examine the relationships of physical activity, 
location specific fat depots (VAT, SAT, and IMAT), and local (as measured in the muscle) 
pro-inflammatory cytokine expression in older adults.  We hypothesized the active 
individuals would have both lower VAT and IMAT as well as decreased local 
inflammation.  We further hypothesized that significant relationships would exist between 
VAT, IMAT and local inflammation.  
Methods
Participants
 All participants in this study were part of a larger study examining the differences 
in IMAT, inflammation and mobility in older frail and nonfrail elders. Individuals were 
recruited from local community groups, health care clinics, mailing and word of mouth 
referrals. To minimize the contribution of sex or obesity to VAT, IMAT and inflammation 
inclusion criteria required subjects to be female, over the age of 65, have a BMI of less 
then 30, and willing to undergo a percutaneous needle muscle biopsy. Exclusion criteria 
were any history or diagnosis of diabetes, COPD, active cancer, chronic heart failure, 
chronic infection, heart disease or any other condition known to increase systemic 
inflammatory levels.  Participants were also excluded if they were using any medication 
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known to influence inflammation such as tobacco products, corticosteroids, non-steroidal 
anti-inflammatories, hormone replacements or anti-coagulants.  Any individuals on statin 
medications were asked to hold all statin medication for at least 7 days prior to the 
muscle biopsy. 
Study Design
 Potential participants completed a telephone screen followed by an in-person 
screen to determine eligibility. Prior to all in person screening tests, all eligible volunteers 
signed an institution-approved consent form.  Immediately after the in-person screening 
demographic data were gathered from the participants and participants were asked to fill 
out the Physical Activity Scale for the Elderly (PASE).42-44  The PASE is a self-report 
measure that has been shown to be reliable and valid method for estimating levels of 
physical activity in older adults and includes not only planned physical activity but also 
considers the contribution of leisure time, volunteer, and housework activities.42-44  After 
completing the PASE participants were scheduled for an MRI within 2 weeks.  
Individuals underwent a MRI scan of their legs and abdomen to determine the cross 
sectional area of abdominal VAT and SAT and IMAT found within the legs. Within one 
week of the MRI a muscle biopsy was performed to determine local muscular levels of 
pro-inflammatory cytokines. 
SAT, VAT and IMAT Determination
 MRI methods for determination of lean muscle mass and IMAT have been 
described in detail elsewhere.45 Briefly magnetic resonance imaging (MRI) was used to 
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determine the SAT and VAT at a single abdominal axial cross section of L4-L5 and 
bilateral imaging of the thighs was performed to determine the average cross sectional 
area of IMAT. 
 SAT and VAT determination. Subjects were placed supine in a 3.0 Tesla whole 
body MR imager (Siemens Trio, Siemens Medical, Erlangen, Germany). Imaging of the 
abdomen was performed with a single axial slice at the L4-5 level using a 2D gradient 
recalled echo (GRE) three-point Dixon sequence (TR=20ms, TE=2.75/3.95/5.15ms, 
matrix size=192x156).  Localization of the slice to the L4-5 level was performed with a 
sagittal T2 weighted turbo-spin echo (TSE) sequence prior to the axial abdomen imaging. 
Two acquisitions were performed in a single breath hold and all imaging was performed 
with a phase array torso/abdomen coil. Separate fat and water images were created with 
custom software using the three-point Dixon method.45  A tissue model was then used to 
calculate estimates of total fat and nonfat volume fractions on a per-pixel basis, which 
were displayed in image form. SAT was determined by manually defining a region of 
interest (ROI) between the skin and the fasical boarder external to the abdominal wall. 
VAT was determined by manually defining a region of interest within the fascial plane of 
the internal abdominal wall. Total SAT and VAT tissue was calculated by summing the 
value of percent fat fraction over all pixels within the ROI using custom-written image 
analysis software (MATLAB; The MathWorks, Natick, Massachusetts). This sum was 
multiplied by the area of each pixel to give total SAT and VAT cross-sectional area within 
the ROI.
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 IMAT determination. The legs were scanned in a coronal plane and the midpoint 
of the thigh was determined and defined as half way between the superior margin of the 
femoral head and the inferior margin of the femoral condyles. Axial imaging (5mm thick 
slices at 1 cm intervals) of the legs was then performed over 1/2 the length of the femur, 
centered at the midpoint of the thigh. Eleven images from the middle 1/3 of each thigh 
were used to determine average cross-sectional area (cm2) of IMAT. Manual tracing 
eliminated subcutaneous fat and bone and isolated the fascial border of the thigh to create 
a subfascial ROI. Total IMAT was calculated by summing the value of percent fat 
fraction over all pixels within the ROI using custom-written image analysis software 
(MATLAB; The MathWorks, Natick, Massachusetts). This sum was multiplied by the 
area of each pixel to give total IMAT within the ROI. This method accurately measures 
fat and lean tissue in pixels that contain both by allowing fractional contributions to the 
fat and lean tissue CSA calculations.46 This allows microscopic fat within muscle tissue 
as well as thin planes of fat adjacent to fascial planes to be accurately taken into account, 
even when image resolution is inadequate to delineate these visually.  The same 
investigator, blinded to slice location, performed measurements of individual participants 
SAT, VAT and IMAT. This technique has demonstrated high levels of intrarater reliability,
47 test-retest reliability,48, 49 and concurrent validity when compared to imaging of a 
cadaveric phantom limb.47 
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Muscle Biopsy
 All muscle biopsies were performed within one week of the MRI scans.  
Participants were asked to refrain from any strenuous activity in the 48 hours prior to the 
muscle biopsy. All individuals presented in the morning after a 12 hour fast for a 
percutaneous needle biopsy.50, 51  The skin and fascia 12-15 cm above the lateral tibio-
femoral joint space was anesthetized with 5cc of 1% lidocaine and a small incision was 
made.  The biopsy needle was inserted 3-5 cm beyond the fascia into muscle and three 
passes (bites) made to yield approximately 200 mg of muscle tissue.  Following biopsy, 
deep pressure was applied for 20 minutes, followed by a steri-strip bandage and pressure 
dressing.  The sample obtained was dissected free from blood and visible fat, snap frozen 
in liquid nitrogen and stored at -80 C until analysis.  
Pro-inflammatory Cytokine Measures in the Muscle. 
 IL-6 and TNF-a were the dependent variables chosen to represent pro-
inflammatory cytokines levels within the muscle.  In order to measures the expression of 
these pro-inflammatory cytokines within the muscle both mRNA and protein expression 
of IL-6 and TNF-a were determined. To determine the mRNA expression of IL-6 and 
TNF-a in the muscle tissue of the participants total RNA, cDNA synthesis and real-time 
qPCR were conducted as previously reported. 52 Total RNA was extracted by 
homogenizing 15-20 mg muscle tissue with a hand-held homogenizing dispenser 
(PowerGen 125; Fisher Scientific) in a solution containing 0.75 ml Tri reagent (LS; 
Molecular Research Center, Cincinnati, OH) and 0.25 ml nuclease free water. The RNA 
was separated into an aqueous phase using 0.2 ml of chloroform and precipitated using 
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0.5 ml of isopropanol. Isolated RNA was washed with 1 ml of 75% ethanol, dried, and 
then suspended in a known amount of nuclease-free water (1.5 ml/mg tissue). RNA was 
DNase-treated using a commercially available kit (TURBO DNase-free, Life 
Technologies, Carlsbad, CA). RNA concentration was determined with a NanoDrop 2000 
(ThermoFisher Scientific, Waltham, MA). Afterwards, 0.5 mg of total RNA was reverse 
transcribed into cDNA according to the manufacturers’ directions (iScript, BioRad, 
Hercules, CA). All isolated RNA and cDNA samples were stored at -80°C until analyzed. 
Real-time qPCR was carried out with an Applied Biosystems 7900HT fast sequence 
detection system. Taqman pre-designed primers (IL-6 and TNF-a) were purchased from 
Life Technologies. Values were normalized to beta 2-microglobulin then fold change 
values were calculated using the 2-∆∆Ct method.53  
 To determine protein expression of IL-6 and TNF-a in the muscle western blots 
were used.  Frozen muscle tissue was homogenized in a buffer cocktail with protease 
inhibitors in a pre-chilled glass tube under ice. Muscle homogenates were centrifuged at 
6000 rpm for 10 minutes at 4°C and the supernatant was subsequently collected and 
transferred to a new microcentrifuge tube. Total protein concentration for each sample 
was determined on a spectrophotometer using a colorimetric protein assay (Bio-Rad; 
Bradford) and an albumin standard curve. Whole muscle homogenates were diluted 1:1 in 
a 2X sample buffer. Homogenates were loaded at equal protein concentration on a 
Criterion Tris-HCL pre-cast polyacrylamide gel (Bio-Rad) and subjected to SDS-PAGE 
(150V) for 1h in running buffer. Each gel contained alternating samples loaded in 
duplicate, and a molecular weight ladder.  An internal control was loaded in duplicate on 
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each gel for band normalization and comparisons across blots. Protein was transferred 
(50V; 1h) to a polyvinylidene diflouride membrane in ice cold transfer buffer then 
blocked for 1h at room temperature with 2% nonfat dry milk (NFDM) in Tris-buffered 
saline in 0.1% Tween-20 (TBST). Membranes were incubated overnight in primary 
antibody diluted in 2% NFDM in TBS. The next morning, blots were rinsed in TBST for 
5 minutes, rocked in secondary antibody for 1 hour at room temperature in 2% NFDM in 
TBS then serially washed (15 minutes, 4 x 5 minutes) in TBST.  Chemiluminescence 
reagent (ECL Plus, GE Healthcare) was applied to each blot for 5 minutes. Optical 
density measurements were obtained with a digital imager (Bio-Rad). Membranes were 
stripped (Restore PLUS, Thermo Scientific) of primary and secondary antibodies then re-
probed for a-tubulin (1:50,000; Sigma Aldrich, St. Louis, MO). Densitometric analysis 
was performed using Quantity One software (Bio-Rad).  After subtracting out 
background, all western blot data were normalized to the internal control and replicate 
samples were averaged. The following antibodies were used in this experiment: IL-6 
(1:200; Santa Cruz Biotechnology, Santa Cruz, CA), TNF-a (1:500; Cell Signaling, 
Boston, MA), and Toll-like receptor 4 (1:500; Santa Cruz Biotechnology).  Donkey anti-
rabbit and goat anti-mouse IgG horseradish peroxidase-conjugated secondary antibodies 
(1:6000) were purchased from Santa Cruz Biotechnology.  
Data Analysis
 Data were analyzed with SPSS Statistics 20.0 (SPSS, Chicago, IL). Descriptive 
statistics were calculated for demographic variables.  To examine our hypothesis of the 
relationships between activity, fat depots, and inflammation pearson product correlations 
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were used.  The correlations between activity levels, BMI (a measure of total body fat), 
VAT, SAT, IMAT, mRNA and protein expression of TNF-a and IL-6 within the muscle of 
all participants were calculated. The level of significance was set at p<.05. 
Results
 Participant demographics are presented in Table 4.1. Fourteen women completed 
the MRI’s and biopsies and were thus included in this study.  Three women had previous 
abdominal surgery creating artifact in the MRI that precluded us from obtaining VAT or 
SAT measurements. IL-6 mRNA was undetectable (i.e., not amplified within 40 PCR 
cycles) for one individual.  Therefore the results presented are for 11 persons for VAT and 
13 for IL-6.
There were significant (p<.05) correlations between BMI and all body fat depots. 
(VAT (r=0.80), SAT(r=0.57) and IMAT (r=0.83).) BMI was also significantly negatively 
associated with activity levels as measured by the PASE (r= -0.52). IL-6 mRNA 
expression was significantly associated with IMAT (r=0.64), VAT (r=0.80), BMI (r=0.62) 
and activity levels (r = -0.50).  IL-6 protein expression revealed a trend toward 
significance with activity levels (r = -0.43 p=0.06).  TNF-a mRNA expression was 
significantly associated with SAT (r=0.54) and BMI (r=0.48) but was not associated with 
activity levels.  TNF-a protein expression was not significantly associated with any 
measures.
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BMI  (Kg/m2) 23.8 (2.9)
IMAT (cm2) 17.1 (5.2)
VAT   (cm2) 108.5 (69.6)
SAT   (cm2) 185.1 (55.7)
PASE (minutes of 
activity/week) 140 (96)
BMI = Body Mass Index; MPPT = modified physical performance test score; IMAT= 
thigh intramuscular adipose tissue average cross sectional area; VAT = cross sectional 
area of visceral adipose tissue; SAT = subcutaneous adipose tissue; PASE = Physical 
Activity Scale self reported minutes of activity/week
Discussion
 In this study we sought to determine the relationships of physical activity, location 
specific fat depots (VAT, SAT, and IMAT), and local (as measured in the muscle) pro-
inflammatory cytokine expression in older adults.  We hypothesized that active 
individuals would have both lower VAT and IMAT as well as decreased local 
inflammation.  We further hypothesized that significant relationships would exist between 
VAT, IMAT and local inflammation. 
The Relationship of VAT, IMAT and Inflammation
 The most novel finding of this study was that IL-6 mRNA expression within the 
muscle was correlated with BMI, VAT and IMAT depots and with self-reported physical 
activity levels in older nonobese females. This suggests that pro-inflammatory cytokines 
within the muscle are associated both with total body fat as well as local fat depots and 
activity levels. While BMI, VAT, and IMAT have been shown to be highly correlated in 
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obese individuals this has not been reported in those with BMI level in the normal range. 
Our findings suggest that fat deposition in the muscle even in nonobese individuals is
associated with a surrogate measure of total body adiposity (BMI) and with VAT. While 
previous work has demonstrated that up to 30% of circulating levels of IL-6 may be 
released from adipose tissue in obese subjects,18 our data suggest that even in the absence 
of obesity, IL-6 mRNA expression in the muscle is associated with adipose deposition. 
Our findings are in agreement with Beasly et al., who reported the relationships of 
circulating IL-6 and TNF-a with VAT, SAT and IMAT in older adults. 16  In this study of 
over 1,000 older adults they found that all body fat measures (VAT, SAT, and IMAT) were 
positively and significantly correlated with circulating levels of IL-6.  They also 
identified a trend towards increasing IL-6 with increasing levels of IMAT.16 While our 
study is much smaller than Beasly et al. it is the first that we are aware of that examines 
the relationships of Il-6 and TNF-a mRNA and protein expression in locomotor muscle 
and multiple fat depots. 
Inflammation, IMAT, and Activity
 Increased levels of IMAT are associated with decreased strength and mobility in 
both younger and older adults.32, 34, 35, 37, 45, 54 Multiple authors have theorized that these 
negative associations may be due to increased release of TNF-a or IL-6 from IMAT.16, 36, 
37, 40, 41 While we did not find any relationship between any fat depots and IL-6 protein 
expression within the muscle we did find significant correlations between IL-6 mRNA 
expression within the muscle and both IMAT and VAT.  Increased basal levels of pro-
inflammatory cytokines such as IL-6 is one of the most important physiologic correlates 
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of frailty55, 56 and increases in circulating levels of IL-6 are known to be associated with 
decreased strength,13, 57 mobility,58, 59 and activity levels in older adults.60 We also found 
that both IL-6 mRNA and protein expression within the muscle were significantly 
correlated with self-reported activity levels.  Several studies have reported significant 
correlations between increased activity levels and decreased levels of circulating pro-
inflammatory cytokines.15, 61, 62 Our findings along with previous work suggests that 
increasing activity levels may be one treatment for combating chronic inflammation in 
older adults.  Exercise interventions may mitigate increased IMAT in locomotor muscle 
of this population.  Modest walking has been shown to prevent increased IMAT in older 
adults63 and combining aerobic and resistance training can decrease IMAT 
accumulation64
 While previous research suggests little to no change in circulating cytokines with 
exercise interventions, large decreases in pro-inflammatory cytokines within the muscle 
have been reported.25, 65 Although changes in VAT and IMAT were not examined in these 
studies, decreases in VAT or IMAT provide a potential explanation for the muscle specific 
decreases in pro-inflammatory cytokines that accompany exercise training. Further 
studies are needed to elucidate the relationships of increased activity levels, IMAT and 
inflammation within the muscle. 
Limitations and Directions for Future Research
Due to the limited number of participants in the present study, our results should 
be interpreted cautiously.  However, all participants were carefully screened to minimize 
the effect of medications or illnesses known to influence inflammatory markers, and 
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therefore these results may in fact be conservative. The inclusion of individuals with 
known systemic disease may uncover more robust findings.  While it is possible that 
some participants had an undiagnosed illness that influenced our results, our agreement 
with previous research support our findings, that both VAT and IMAT as well as physical 
activity levels influence pro-inflammatory cytokines found within the muscle of older 
women, even in the absence of obesity lend credence to our findings.  Future research 
should corroborate our findings with larger sample sizes, and importantly determine 
whether therapeutic interventions aimed at decreasing inflammation affect ectopic fat 
deposition or vice-versa.  Such information will help to inform the mechanisms that link 
excessive adipose tissue to muscle and mobility decline in older adults and provide 
targets for therapeutic interventions. 
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